Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 2/20 | 0.41 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.40 |
| ▸ | LIPC | P11150 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037590 | 1.00 | CHRM4 (0.41) | CHRM4NCF1CYP8B1LIPGLIPC | |
| SCHEMBL5037545 | 0.95 | CHRM4 (0.40) | CHRM4NCF1CYP8B1LIPGKMT2A | |
| SCHEMBL5037542 | 0.95 | CHRM4 (0.40) | CHRM4NCF1CYP8B1LIPGKMT2A | |
| SCHEMBL5040526 | 0.90 | NCF1 (0.44) | CHRM4NCF1CYP8B1KMT2AMEN1 | |
| SCHEMBL5040485 | 0.90 | NCF1 (0.44) | CHRM4NCF1CYP8B1KMT2AMEN1 | |
| SCHEMBL5040488 | 0.90 | NCF1 (0.44) | CHRM4NCF1CYP8B1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL5035823 | 0.89 | CHRM4 (0.42) | CHRM4NCF1CYP8B1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL5035821 | 0.89 | CHRM4 (0.42) | CHRM4NCF1CYP8B1KMT2AMEN1 | |
| SCHEMBL5040535 | 0.89 | PDE3B (0.40) | CHRM4LIPGLIPCKMT2AMEN1 | |
| SCHEMBL6377286 | 0.89 | PDE3B (0.40) | CHRM4LIPGLIPCKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | CHRM4 2051/4885NCF1 1052/4885CYP8B1 2803/4885 |
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | CHRM4 2051/4885NCF1 1052/4885CYP8B1 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.